Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.

Evan S DellonMarc E RothenbergMargaret H CollinsIkuo HiranoMirna ChehadeAlbert J BredenoordAlfredo J LucendoJonathan M SpergelSeema AcevesXian SunMatthew P KosloskiMohamed A KamalJennifer D HamiltonBethany BeazleyEilish McCannKiran PatelLeda P MannentElizabeth LawsBolanle AkinladeNikhil AminWei Keat LimMatthew F WippermanMarcella RuddyNaimish PatelDavid R WeinreichGeorge D YancopoulosBrad ShumelJennifer MaloneyAngeliki GiannelouArsalan Shabbir

Published in: The New England journal of medicine (2022)

Among patients with eosinophilic esophagitis, subcutaneous dupilumab administered weekly improved histologic outcomes and alleviated symptoms of the disease. (Funded by Sanofi and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT03633617.).

Keyphrases

atopic dermatitis
chronic rhinosinusitis
young adults
physical activity
sleep quality
type diabetes
metabolic syndrome
depressive symptoms
weight loss